A global leader in eye care, the company is involved in developing treatments for rare ocular diseases, holding 18 FDA-approved drugs and 2 orphan drug designations across various conditions.
2
Orphan Designations
18
FDA Approvals
10
Rare Diseases
0
News Articles
| Disease | Drug(s) | Designation | Approved |
|---|---|---|---|
| BMP4-related ocular growth disorder | Alomide Ophthalmic Solution | Orphan Designation | - |
| endogenous Cushing syndrome | Durezol | Orphan Designation | - |
| endogenous depression | Durezol | Orphan Designation | - |
| exogenous Cushing syndrome | Durezol | Orphan Designation | - |
| exogenous ochronosis | Durezol | Orphan Designation | - |
| eye adnexa disorder | Alomide Ophthalmic Solution | Orphan Designation | - |
| intellectual developmental disorder with ocular anomalies and distinctive facial features | Alomide Ophthalmic Solution | Orphan Designation | - |
| ocular growth disorder | Alomide Ophthalmic Solution | Orphan Designation | - |
| ocular vascular disorder | Alomide Ophthalmic Solution | Orphan Designation | - |
| vernal keratoconjunctivitis | Alomide Ophthalmic Solution | Orphan Designation | - |